Which of the following is a guideline-recommended, first-line therapy to reduce cardiovascular disease risk in patients with diabetes?
Better luck next time!
The correct answer is empagliflozin. Empagliflozin, canagliflozin, and litraglutide are all recommended as first-line therapies for reducing CVD risk in patients with diabetes. For more information, listen to our podcast with Dr Daniel Einhorn about treating CVD in patients with diabetes here.
You are correct!
Empagliflozin, canagliflozin, and litraglutide are all recommended as first-line therapies for reducing CVD risk in patients with diabetes. For more information, listen to our podcast with Dr Daniel Einhorn about treating CVD in patients with diabetes here.